Slow particle dissolution may limit lung absorption of inhaled pharmaceuticals in the lungs Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
Lung deposition of an aerosol produced by a new inhalation device for ventilated patients Source: Eur Respir J 2005; 26: Suppl. 49, 88s Year: 2005
Calculation of peripheral airspace dimensions from deposition of inhaled nanoparticles Source: International Congress 2016 – Monitoring airway diseases with different tools Year: 2016
Effect of breath-actuated mechanism on the emitted particle characteristics and lung deposition of a fixed combination drug Source: International Congress 2017 – Inhalers and their use Year: 2017
Deposition of aerosols in the lung periphery of patients with lung emphysema Source: Eur Respir J 2001; 18: Suppl. 33, 212s Year: 2001
Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011
Functional respiratory imaging assessment of the aerosol deposition of inhaled levofloxacin in cystic fibrosis lungs Source: Virtual Congress 2021 – Cystic fibrosis Year: 2021
Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
LATE-BREAKING ABSTRACT: Effect of inhalation profiles and throat geometries on predicted lung deposition of budesonide and formoterol (BF) when inhaled through two different devices Source: International Congress 2014 – Innovative technology and techniques in respiratory function Year: 2014
Controlled inhalation improves total and peripheral lung deposition in CF Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis Year: 2019
Revealing the regional localization and lung retention of inhaled drugs Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018
No evidence electric charge increases inhaled ultrafine particle deposition in human lungs Source: Virtual Congress 2020 – Occupational and environmental causes of respiratory disease Year: 2020
Efficient deposition and absorption of orally inhaled indacaterol in the lungs Source: Annual Congress 2011 - COPD management Year: 2011
Lung deposition distribution in astmatic patients of inhaled steroids when inhaled at the same time or 15 minutes after formoterol Source: Eur Respir J 2004; 24: Suppl. 48, 502s Year: 2004
Pressure supported nasal inhalation improving penetration of particles into the human lung Source: Annual Congress 2012 - Going with the flow: assessment and evaluation of airway function and its role in patient management Year: 2012
Measuring peripheral lung dimensions with the deposition of aerosol nanoparticles Source: Virtual Congress 2021 – Management of chronic cough and obstructive diseases Year: 2021
Blood eosinophils do not predict inhaled budesonide response in bronchiectasis Source: Eur Respir J, 56 (3) 2002210; 10.1183/13993003.02210-2020 Year: 2020
Numerical simulation of the effect of inhalation parameters and disease severity on the deposition of dry powder aerosol drugs in COPD patients Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Lung deposition of inhaled radio-labelled human insulin Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016 Year: 2017